Omics Technologies: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Omics Technologies
Largest movements
- Cash +€28,618
up €28,618 (+89096.2%), from €32 to €28,650
mainly Trade debts (+€21,767) and Stocks and contracts (+€6,875)
- Stocks and contracts -€6,875
down €6,875 (-31.0%), from €22,192 to €15,317
- Receivables within one year +€854
up €854 (+6.2%), from €13,810 to €14,664
of which Other amounts receivable: +€854
- Trade debts +€21,767
up €21,767 (+292.0%), from €7,455 to €29,222
- Profit (loss) carried forward +€1,773
up €1,773 (+11.9%), from €14,942 to €16,715
- Other debts -€942
down €942 (-6.8%), from €13,872 to €12,930
- Gross operating margin +€7,996
up €7,996, from -€4,452 to €3,544
- Depreciation -€276
no longer reported in 2025 (was €276)
- Other operating charges -€179
down €179 (-9.7%), from €1,842 to €1,663
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €36,269 | €58,867 | +€22,597 | +62.3% |
| Fixed assets | 21/28 | €235 | €235 | = | 0.0% |
| Financial fixed assets | 28 | €235 | €235 | = | 0.0% |
| Current assets | 29/58 | €36,034 | €58,632 | +€22,597 | +62.7% |
| Stocks and contracts in progress | 3 | €22,192 | €15,317 | -€6,875 | -31.0% |
| Stocks | 30/36 | €22,192 | €15,317 | -€6,875 | -31.0% |
| Amounts receivable within one year | 40/41 | €13,810 | €14,664 | +€854 | +6.2% |
| Trade receivables | 40 | €10,905 | €10,905 | = | 0.0% |
| Other amounts receivable | 41 | €2,905 | €3,759 | +€854 | +29.4% |
| Cash at bank and in hand | 54/58 | €32 | €28,650 | +€28,618 | +89096.2% |
| Total equity and liabilities | 10/49 | €36,269 | €58,867 | +€22,597 | +62.3% |
| Equity | 10/15 | €14,942 | €16,715 | +€1,773 | +11.9% |
| Profit (loss) carried forward | 14 | €14,942 | €16,715 | +€1,773 | +11.9% |
| Amounts payable | 17/49 | €21,327 | €42,151 | +€20,825 | +97.6% |
| Amounts payable within one year | 42/48 | €21,327 | €42,151 | +€20,825 | +97.6% |
| Trade debts | 44 | €7,455 | €29,222 | +€21,767 | +292.0% |
| Suppliers | 440/4 | €7,455 | €29,222 | +€21,767 | +292.0% |
| Other amounts payable | 47/48 | €13,872 | €12,930 | -€942 | -6.8% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €276 | - | -€276 | |
| Other operating charges | 640/8 | €1,842 | €1,663 | -€179 | -9.7% |
| Gross operating margin | 9900 | -€4,452 | €3,544 | +€7,996 | |
| Operating profit (loss) | 9901 | -€6,570 | €1,881 | +€8,450 | |
| Financial charges | 65/66B | €110 | €108 | -€2 | -2.1% |
| Recurring financial charges | 65 | €110 | €108 | -€2 | -2.1% |
| Profit (loss) for the period before taxes | 9903 | -€6,680 | €1,773 | +€8,453 | |
| Profit (loss) for the period | 9904 | -€6,680 | €1,773 | +€8,453 | |
| Profit (loss) for the period to be appropriated | 9905 | -€6,680 | €1,773 | +€8,453 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.